Cancer biology has long treated p53 as a straightforward tumor suppressor—a molecular brake that halts runaway cell growth. New evidence now complicates that narrative in ways that matter enormously for future drug development: under specific genetic stress, p53 appears to actively maintain the metabolic machinery cancer cells need to survive, which could undermine therapeutic strategies targeting RNA methylation enzymes.
This PNAS study identifies a noncanonical function of wild-type p53 triggered when the m18A RNA methyltransferase METTL5 is depleted. Rather than executing its classical apoptotic or cell-cycle arrest programs, nuclear p53 in this context instead sustains mitochondrial oxidative phosphorylation—preserving cellular energy output that would otherwise collapse. In practical terms, the loss of METTL5 initiates a tumor-suppressive signal, but p53 steps in to override that suppression by keeping mitochondrial respiration intact. The mechanistic implication is that p53's metabolic moonlighting actively counteracts what should be a therapeutically exploitable vulnerability.
This finding lands in a rich but still-contested landscape around p53 and cellular metabolism. Over the past decade, researchers have established that p53 regulates glycolysis, fatty acid oxidation, and mitochondrial biogenesis through transcriptional targets like TIGAR and SCO2—but those roles were understood as secondary to its canonical tumor-suppressive functions. The idea that p53 could actively rescue tumor cell viability by shoring up mitochondrial respiration in response to an upstream loss-of-function event represents a meaningful conceptual shift. For adults tracking longevity science, METTL5's role in ribosomal RNA modification also connects to translational fidelity and cellular aging. Key limitations apply: the extent to which this mechanism operates across diverse tumor types, and whether it holds in primary human tissue rather than engineered cell models, remains unresolved. Nonetheless, this is a finding that drug developers targeting epitranscriptomic enzymes cannot responsibly ignore.